How do you choose bridging therapy prior to CAR-T leukapheresis?

There is a lack of uniform clarity around terminology here. To avoid confusion, I prefer using "debulking" for treatment that is administered prior to T-cell apheresis, and "bridging" for treatment administered after apheresis to bridge the patient during manufacture to maintain disease control prior to CAR-T administration.

Treatment selection differs somewhat in these two scenarios. For patients unable to proceed to T-cell apheresis due to disease burden, tempo, and performance status, treatment selection must both be active in treating the lymphoma but also not render the patient lymphopenic (and in so doing prevent successful T-cell apheresis). Oftentimes, rituximab and polatuzumab (without bendamustine, given its effect on lymphocyte c...